Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8974847 | 0.83 | PDE2A (0.60) | PDE2AKDM4ESMN1; SMN2CES2ALDH1A1 | |
| SCHEMBL6681459 | 0.83 | CES2 (0.51) | PDE2AKDM4ESMN1; SMN2CES2ALDH1A1 | |
| SCHEMBL8974843 | 0.83 | PDE2A (0.60) | PDE2AKDM4ESMN1; SMN2CES2ALDH1A1 | |
| SCHEMBL6702844 | 0.83 | CES2 (0.51) | PDE2AKDM4ESMN1; SMN2CES2ALDH1A1 | |
| SCHEMBL6681467 | 0.83 | CES2 (0.51) | PDE2AKDM4ESMN1; SMN2CES2ALDH1A1 | |
| SCHEMBL6677088 | 0.82 | PDE2A (0.49) | PDE2AKDM4ESMN1; SMN2CES2ALDH1A1 | |
| SCHEMBL4633442 | 0.81 | PDE2A (0.63) | PDE2AKDM4ECES2ALDH1A1HPGD | |
| SCHEMBL4633445 | 0.81 | PDE2A (0.63) | PDE2AKDM4ECES2ALDH1A1HPGD | |
| SCHEMBL6400526 | 0.79 | PDE2A (0.47) | PDE2AKDM4ESMN1; SMN2CES2ALDH1A1 | |
| SCHEMBL6679457 | 0.79 | CES2 (0.51) | PDE2AKDM4ESMN1; SMN2CES2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040249220-A1 | Process for producing optically active 2-alkoxy-1-(trifluoromethyl-substituted phenyl) ethanol derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-12-09 | — | — | US | claimed |
| WO-2004037760-A2 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 2-ALKOXY-1-(TRIFLUOROMETHYL-SUBSTITUTED PHENYL)ETHANOL DERIVATIVES | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-05-06 | — | — | WO | claimed |
| US-20040249220-A1 | Process for producing optically active 2-alkoxy-1-(trifluoromethyl-substituted phenyl) ethanol derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
| WO-2004037760-A2 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 2-ALKOXY-1-(TRIFLUOROMETHYL-SUBSTITUTED PHENYL)ETHANOL DERIVATIVES | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249220-A1 | Process for producing optically active 2-alkoxy-1-(trifluoromethyl-substituted phenyl) ethanol derivatives | ADH1A, ADH1C, ADH5 | PDE2A 3242/4885KDM4E 74/4885SMN1; SMN2 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.